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ORIGINAL ARTICLE
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Background: Given the interconnectivity of Brazil with the rest of the world, Zika virus (ZIKV) infections
have the potential to spread rapidly around the world via viremic travellers. The extent of spread depends on
the travel volume and the endemicity in the exporting country. In the absence of reliable surveillance data, we
did mathematical modelling to estimate the number of importations of ZIKV from Brazil into Europe.
Design: We applied a previously developed mathematical model on importations of dengue to estimate the
number of ZIKV importations into Europe, based on the travel volume, the probability of being infected at
the time of travel, the population size of Brazil, and the estimated incidence of ZIKV infections.
Results: Our model estimated between 508 and 1,778 imported infections into Europe in 2016, of which we
would expect between 116 and 355 symptomatic Zika infections; with the highest number of importations
being into France, Portugal and Italy.
Conclusions: Our model identified high-risk countries in Europe. Such data can assist policymakers and
public health professionals in estimating the extent of importations in order to prepare for the scale up of
laboratory diagnostic assays and estimate the occurrence of GuillainBarre´ Syndrome, potential sexual
transmission, and infants with congenital ZIKV syndrome.
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Introduction
In May 2015, an outbreak of Zika virus (ZIKV) infections
was first reported in Brazil, and by December 2015,
500,0001,500,000 ZIKV infections were estimated (1). By
October 2015, increasing number of microcephaly cases
and other neonatal malformations were thought to
be associated with ZIKV infections (2). On 1 February
2016, the clusters of microcephaly and GuillainBarre´
Syndrome (GBS) cases in likely association with ZIKV
infections were declared a public health emergency of
international concern (3). Given the interconnectivity of
Brazil with the remainder of the world, ZIKV has the
potential to spread rapidly around the world via viremic
travellers (4). The extent of spread depends on the travel
volume to destination countries and the endemicity in the
exporting country (57). Because of the mild clinical
manifestations of the disease in the vast majority of cases,
ZIKV infections in individual travellers are unlikely to lead
to cancellation of flights or disruption of holiday/business
plans. Furthermore, 80% of all infections are thought to be
asymptomatic. The biggest concern is the spread to areas
where suitable mosquito vectors exist and importation
could trigger further outbreaks. However, given that sexual
transmission of ZIKV has been reported, the spread of
ZIKV via viremic travellers to areas without the Aedes
mosquitoes is equally of concern (8). Sexual transmission to
non-travelling contacts in Europe could propagate ZIKV
infections in Europe, resulting in a potential upsurge of GBS
cases as a result of imported ZIKV infections and putting
pregnant women at risk. Therefore it is important to
estimate the potential number of travellers returning to
Europe with ZIKV infections.
ZIKV infections remain underdiagnosed and under-
reported because of the non-specific and mild manifestations
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and lack of widely available diagnostic assays. Therefore,
for the time being any estimates on the epidemiological
burden remain crude estimates. We based our calculations
on the published estimate of 500,0001,500,000 infections
(both symptomatic and asymptomatic) for the year 2015 in
Brazil (1). Reliance on reported events of importation will
only underestimate the true importation risk as most
imported cases will not be detected and reported, unless
the clinical manifestations are more severe. In the absence
of reliable surveillance data, mathematical modelling is
necessary to estimate the number of importations of ZIKV
from Brazil into Europe.
Methods
We applied a previously developed mathematical model on
exportations to estimate the number of ZIKV importa-
tions into Europe (9). This model takes into account the
travel volume, the probability of being infected at the time
of travel, the population size of Brazil, and the estimated
incidence of ZIKV infections (estimated numbers over
population size). The model was previously developed to
estimate the risk of dengue acquisition in international
travellers (1012), and has also been applied to estimate
polio virus importations (13).
The number of travellers departing from Brazilian
airports on commercial flights to each of the European
countries was obtained from the International Air Trans-
port Association (IATA) for the year 2012. As we only had
access to the year 2012 flight data, the travel pattern of
outgoing flights in 2015 or 2016 was assumed to not have
changed significantly.
We calculated the force of infection, l(t) from the
assumption that there had been 0.5 to 1.5 million ZIKV
infections in Brazil. In addition, we assumed that the
seasonal distribution of cases followed the same as for
dengue, given that both viral infections share the same
Aedes vectors, and initial observations have claimed that
ZIKV seems to follow the path of dengue (14). As popu-
lations of Aedes aegypti and Aedes albopictus are climate
sensitive and display a seasonal pattern in Brazil (1517),
ZIKV infections are likely to exhibit the same seasonal
pattern as dengue in Brazil.
The steps for the mathematical models are detailed in
the Supplement. In brief, we first fitted a continuous
function to the time distribution of notified cases from
which we estimate the force of infection l(t). The product
of the force of infection by the fraction of susceptible
individuals is the number of reported cases.
The individual risk of acquiring the infection from the
ZIKV-infected mosquitoes, Risk (t), is given by
RiskðtÞ ¼ 1  expð
Zt2
t1
kðtÞdtÞ (1)
where, again, l(t) is the force of infection or incidence
density rate; t1 is, in the case of travellers, the moment they
arrive at the endemic area; and t2 is the moment they
depart. Note that the concept of risk expressed in equation
(1) means the risk for travellers that remain in the ZIKV
endemic area for the period between t1 and t2. For locals,
t2t1 is the time interval considered for the risk calculation
(e.g. the month-by-month risk calculation).
The risk varies with time. As Fig. 1 shows, this risk is
highest in the months with the highest number of reported
dengue cases (as a consequence of a higher density of
infected mosquitoes), at its maximum by the month of
April. This would also fit with the observation of the onset
of excess microcephaly cases in October 2015 (69 months
after the high season of January to April).
As the function Risk (t) represents the individual risk
of acquiring the infection, we can use it as the probability
that one passenger flying from a Brazilian airport is
infected with the ZIKV. By multiplying the individual
probability of being infected by the number of passengers
leaving Brazilian airports, we have the total number of
expected infections that are flying to European countries.
Our model applies to individuals from Brazil travelling
to Europe or travellers having visited Brazil and now
returning to Europe.
Results
Figures 1 and 2 show the resulting curve for the individual
risk of acquiring the infection and the expected number of
ZIKA cases arriving in Europe by month, respectively.
Fig. 1. Calculated per capita risk (probability of being
infected). Risk(t)1exp[l(t)t], where l(t) is the force of
infection.
Fig. 2. Expected number of travellers with Zika virus
infections arriving in Europe by month, in the year 2015.
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Table 1. Estimated imported ZIKV infections from Brazil to Europe based on the 1.5 million and 500,000 ZIKV infections scenarios in 2015
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Total
Individual risk for each
scenario
500 K 0.000146 0.000366 0.000594 0.000617 0.000414 0.00018 5.03E-05 9.06E-06 1.05E-05 9.06E-06 9.06E-06 9.06E-06
1.5 G 0.000511 0.00128 0.00208 0.00216 0.00145 0.000631 0.000176 3.17E-05 3.67E-05 3.17E-05 3.17E-05 3.17E-05
Albania Travellers 9 12 8 9 10 67 1 28 9 13 21 0 187
Expected cases for
each scenario
500 K 0 0 0 0 0 0 0 0 0 0 0 0 0
1.5 G 0 0 0 0 0 0 0 0 0 0 0 0 0
Austria Travellers 1986 1840 2570 2203 24000 2304 2339 3235 3660 2067 2245 0 48449
Expected cases for
each scenario
500 K 0 1 2 1 10 0 0 0 0 0 0 0 14
1.5 G 1 2 5 5 35 1 0 0 0 0 0 0 51
Belgium Travellers 2733 2543 2565 2647 2375 2599 3194 3513 2313 2296 1881 2449 31108
Expected cases for
each scenario
500 K 0 1 2 2 1 0 0 0 0 0 0 0 6
1.5 G 1 3 5 6 3 2 1 0 0 0 0 0 22
Bulgaria Travellers 156 124 67 122 223 159 159 319 69 92 76 158 1724
Expected cases for
each scenario
500 K 0 0 0 0 0 0 0 0 0 0 0 0 0
1.5 G 0 0 0 0 0 0 0 0 0 0 0 0 1
Croatia Travellers 229 271 234 354 491 926 675 597 883 551 201 200 5612
Expected cases for
each scenario
500 K 0 0 0 0 0 0 0 0 0 0 0 0 1
1.5 G 0 0 0 1 1 1 0 0 0 0 0 0 3
Czech Rep Travellers 561 901 1096 1092 1945 1663 1867 1805 2438 1470 1193 1026 17057
Expected cases for
each scenario
500 K 0 0 1 1 1 0 0 0 0 0 0 0 3
1.5 G 0 1 2 2 3 1 0 0 0 0 0 0 11
Denmark Travellers 3384 2151 1878 2015 2880 3274 4052 4421 1971 1506 1531 1725 30788
Expected cases for
each scenario
500 K 0 1 1 1 1 1 0 0 0 0 0 0 6
1.5 G 2 3 4 4 4 2 1 0 0 0 0 0 20
Finland Travellers 1405 799 651 687 833 1026 843 660 374 537 661 0 8476
Expected cases for
each scenario
500 K 0 0 0 0 0 0 0 0 0 0 0 0 2
1.5 G 1 1 1 1 1 1 0 0 0 0 0 0 7
France Travellers 29302 28118 33352 32796 35533 37932 40265 32572 37959 33476 27270 39248 407823
Expected cases for
each scenario
500 K 4 10 20 20 15 7 2 0 0 0 0 0 80
1.5 G 15 36 69 71 52 24 7 1 1 1 1 1 279
Germany Travellers 21552 20305 22563 21564 21872 20226 21372 24965 29920 22872 21713 23703
Expected cases for
each scenario
500 K 3 7 13 13 9 4 1 0 0 0 0 0
1.5 G 11 26 47 47 32 13 4 1 1 1 1 1
Greece Travellers 712 590 1499 1141 1484 1805 2329 1836 2439 1386 646 690 16557
Expected cases for
each scenario
500 K 0 0 1 1 1 0 0 0 0 0 0 0 3
1.5 G 0 1 3 2 2 1 0 0 0 0 0 0 11
Hungary Travellers 472 553 531 714 1190 1244 1437 1617 1282 788 452 465 10745
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Table 1 (Continued )
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Total
Expected cases for
each scenario
500 K 0 0 0 0 0 0 0 0 0 0 0 0 2
1.5 G 0 1 1 2 2 1 0 0 0 0 0 0 7
Italy Travellers 36580 30257 34235 33521 38120 32883 35912 33365 39478 34887 28373 30136 407747
Expected cases for
each scenario
500 K 5 11 20 21 16 6 2 0 0 0 0 0 83
1.5 G 19 39 71 72 55 21 6 1 1 1 1 1 289
Malta Travellers 97 67 61 65 127 86 102 96 73 51 114 108 1047
Expected cases for
each scenario
500 K 0 0 0 0 0 0 0 0 0 0 0 0 0
1.5 G 0 0 0 0 0 0 0 0 0 0 0 0 1
Netherland Travellers 8055 6418 3727 7209 6997 7051 7669 7328 7006 7103 6391 6396 81350
Expected cases for
each scenario
500 K 1 2 2 4 3 1 0 0 0 0 0 0 15
1.5 G 4 8 8 16 10 4 1 0 0 0 0 0 53
Norway Travellers 2423 1488 1409 2034 1728 1826 2479 1943 1677 1305 1354 2116 21782
Expected cases for
each scenario
500 K 0 1 1 1 1 0 0 0 0 0 0 0 4
1.5 G 1 2 3 4 3 1 0 0 0 0 0 0 15
Poland Travellers 1016 760 884 1635 1344 1784 1828 1272 1018 1160 1025 971 14697
Expected cases for
each scenario
500 K 0 0 1 1 1 0 0 0 0 0 0 0 3
1.5 G 1 1 2 4 2 1 0 0 0 0 0 0 10
Portugal Travellers 35079 29220 30250 34716 34795 35512 38984 34306 39754 30603 28926 33905 406050
Expected cases for
each scenario
500 K 5 11 18 21 14 6 2 0 0 0 0 0 80
1.5 G 18 37 63 75 50 22 7 1 1 1 1 1 278
Romania Travellers 610 654 482 513 540 468 448 764 698 646 479 545 6847
Expected cases for
each scenario
500 K 0 0 0 0 0 0 0 0 0 0 0 0 1
1.5 G 0 1 1 1 1 0 0 0 0 0 0 0 5
Serbia Travellers 124 69 83 64 119 115 74 140 57 140 74 75 1134
Expected cases for
each scenario
500 K 0 0 0 0 0 0 0 0 0 0 0 0 0
1.5 G 0 0 0 0 0 0 0 0 0 0 0 0 1
Slovakia Travellers 11 5 8 5 13 14 28 3 20 9 11 3 130
Expected cases for
each scenario
500 K 0 0 0 0 0 0 0 0 0 0 0 0 0
1.5 G 0 0 0 0 0 0 0 0 0 0 0 0 0
Slovenia Travellers 261 26 30 117 172 108 103 117 157 61 96 50 1298
Expected cases for
each scenario
500 K 0 0 0 0 0 0 0 0 0 0 0 0 0
1.5 G 0 0 0 0 0 0 0 0 0 0 0 0 1
Spain Travellers 23205 22487 20259 21545 24095 25562 28821 20111 24405 21842 16803 22603 271738
Expected Cases for
Each scenario
500 K 3 8 12 13 10 5 1 0 0 0 0 0 54
1.5 G 12 29 42 47 35 16 5 1 1 1 1 1 189
Switzerland Travellers 25562 11487 10804 8521 8295 9701 9461 11820 7604 9249 8803 11189 132496
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Table 1 and the Map show the results of the expected
number of ZIKV cases exported to European countries
from Brazil, based on an estimated lower bound of 500,000
and upper bound of 1.5 million ZIKV infections, respectively,
assuming that these ZIKV infections exhibit the same
seasonal pattern as dengue infections. In total, our models
estimated between 508 and 1,778 imported cases, respec-
tively, into all European countries, with the highest
numbers being in France, Portugal, and Italy (Table 1
and Fig. 3). Of these, 80% would likely be asymptomatic;
hence, we would expect between 116 and 355 symptomatic
ZIKV infections.
Conclusions
Our estimates are consistent with those reported by the
European Centre for Disease Control (ECDC). As of 3
March 2016, ECDC had recorded 209 imported cases into
16 European countries, of which 81 were into France, and
32 into Spain (18). Geographical distribution of ZIKV has
steadily broadened since the virus was first detected in
Brazil in 2015. By March 2016, ZIKV transmission had
been reported in 28 countries and territories (19); hence,
the exportation risk will be even higher than we reported.
However, we were not able to calculate such a risk for the
other countries as incidence data for those countries have
not yet been published. Given that Brazil so far has been
the country most affected with the highest absolute
numbers of estimated ZIKV infections, it is justified to
focus our model on Brazil as exporting country only, until
more data are available from other Latin American countries.
A limitation of our study is that the underlying
assumption of our model is the equal distribution of cases
throughout the country, and the equal probability of
travelling throughout the Brazilian population. However,
in early 2015, the geographic concentration of most cases
were in Northeast Brazil  but by late 2015 and early 2016,
the distribution was already much wider spread with all
major cities in Brazil being affected (18, 2022). Hence our
modelled estimates of ZIKV exportations based on travel
volume will be a more accurate reflection of the situation in
2016, assuming that the year 2016 will also see between
500,000 and 1,500,000 ZIKV infections.
According to the French Polynesian case control study
on ZIKV-related GBS, one would expect 24 GBS cases out
of 100,000 ZIKV infections (23). In other words, if these
estimates hold true, one would need to have 5,000 imported
ZIKV infections to see one case of ZIKV-associated GBS
in returning travellers from ZIKV-affected countries.
Given the current exportation numbers estimated to be
no more than 1,800, the probability of a ZIKV-associated
GBS case in Europe in 2015 or 2016 is relatively low.
However, the number of ZIKV-affected countries within
Latin America, the Caribbean, and beyond is rising,
and hence the likelihood of substantial number of return-
ing travellers presenting with GBS is will increase. The trueT
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risk of ZIKV-related infections that can lead to central
nervous system malformations and microcephaly in preg-
nant women is currently unknown, especially for sexual
transmission (24). However, potentially every single vire-
mic male returning traveller could infect his pregnant or
non-pregnant partner, especially in the first 24 weeks
after ZIKV infection (2527). Hence, the Centre for
Disease Control and travel medicine providers have advised
for precautions (abstinence or condoms) to be taken for
men returning home from ZIKV-affected countries, parti-
cularly in the first few weeks after return (28, 29).
An additional cause of concern is the risk of ZIKV
establishing itself in European regions where the presence
of A. albopictus is endemic, in particular for Mediterranean
countries recording increasingly hotter summers (30),
although the ZIKA competence for A. albopictus is not
fully known at this stage.
We identified high-risk countries in Europe, and
policymakers and clinicians need to be aware of such
data. Furthermore, our models can be applied by indi-
vidual countries or by continents alike and used as an
additional tool to estimate the risk of importation based
on the main contributing factors such as travel volume
and the evolving ZIKA endemicity in exporting coun-
tries. Our models help policymakers estimate the extent
of importations in order to prepare for the scale up of
laboratory diagnostic assays and estimate the occurrence
of GBS, potential sexual transmission, and infants with
congenital ZIKA syndrome.
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Fig. 3. Estimated importations of Zika virus infections via travellers from Brazil to Europe in the year 2015, based on a high
estimate of 1,500,000 Zika virus infections in Brazil.
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Paper context
The Zika virus outbreak in Brazil has gripped the world’s
attention. We applied mathematical modelling to estimate
the extent of Zika virus importations from Brazil to Europe
for the year 2016. Our model estimated between 508 and
1,778 imported infections into Europe in 2016, with the
highest number of importations being into France, Portugal,
and Italy. Such data can assist policymakers to scale up
preparatory measures in Europe.
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